Maternal disease control and pregnancy outcomes with anti-CD20 therapy versus natalizumab in multiple sclerosis: a systematic review. (PubMed, Neurol Sci) - Sep 13, 2026 - "Anti-CD20 therapy was associated with lower maternal disease activity than natalizumab during pregnancy, especially for relapse prevention and postpartum MRI suppression. However, evidence regarding fetal and neonatal safety remains limited, warranting cautious individualized treatment decisions and further comparative research."
Journal • Review • CNS Disorders • Multiple Sclerosis • Small for Gestational Age
|
|
Abdulaziz Altamimi; Abdullah Al Mazyad; Abdullah AlTamimi; Abdulrahman Hussain Ghazwani; Ahmed Sami Afash; Atif Eid Alrashidi; Bashayr Arif Almutairi; Leen Essam Almahmoud; Mohammed Essam Shaybah; Mohammed Yousef Almohaimeed; Nawaf Abdulrahman Obaid Alharbi; Nura Waleed Ghibban; Ruwaym Jaber Mohammed Alharbi
|